Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates

Cancer Treatment Reviews · Published 2026-06-18 · DOI 10.1016/j.ctrv.2026.103173

Free full text

Authors (10)

Hamed Wafa, Nils C.H. van Creij, Michael Guenther, Maxim Noeparast, Jose Daniel Subiela, Angelika Terbuch, Dora Niedersuess-Beke, Zoran Culig, Steffen Ormanns, Renate Pichler

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Wafa, H., Creij, N., Guenther, M., et al. (2026). Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103173

Related articles